Item request has been placed!

Item request cannot be made.

Processing Request

Search Results

Display Settings

Results per page: 10

Sort By: Relevance

Filter

Your Filters

Reset filters

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment.

Authors : Jeon, Min Ji¹ (AUTHOR); Yu, Eun Sang¹ (AUTHOR); Kim, Dae Sik¹ (AUTHOR)

Source: Scientific Reports. 11/5/2024, Vol. 14 Issue 1, p1-8. 8p.

Record details

Read Online Read More Add to Saved list

Academic Journal

First-Line Combination with Proteasome Inhibitor-Based Treatment and Zoledronic Acid Is Effective in Reducing Later Fractures in Multiple Myeloma Irrespective of Multiple Myeloma Bone Disease at Diagnosis.

Authors : Eskelinen, Veera¹ (AUTHOR) ; Nivakoski, Elise¹ (AUTHOR) ; Launonen, Kirsi² (AUTHOR)

Source: Hematology Reports. Sep2024, Vol. 16 Issue 3, p529-540. 12p.

Record details

Read Online Read More Add to Saved list

Academic Journal

The Proteasome Inhibitor Marizomib Evokes Endoplasmic Reticulum Stress and Promotes Apoptosis in Human Glioblastoma Cells.

Authors : Kusaczuk, Magdalena¹ (AUTHOR) ; Tyszka, Natalia¹ (AUTHOR); Krętowski, Rafał¹ (AUTHOR)

Source: Pharmaceuticals (14248247). Aug2024, Vol. 17 Issue 8, p1089. 15p.

Record details

Read Online Read More Add to Saved list

Academic Journal

The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer.

Authors : Tilki, Elif Kaya¹ ; Öztürk, Selin Engür²

Source: Istanbul Journal of Pharmacy. Aug2024, Vol. 54 Issue 2, p215-222. 8p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.

Authors : Tang, Wenjiao¹ (AUTHOR); Li, Yan¹ (AUTHOR); Zhang, Li¹ (AUTHOR)

Source: Cancer Medicine. Jul2024, Vol. 13 Issue 14, p1-11. 11p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties.

Authors : Larsson, Peter^1,2 ; De Rosa, Maria Cristina³; Righino, Benedetta³

Source: Scientific Reports. 8/13/2024, Vol. 14 Issue 1, p1-18. 18p.

Record details

Read Online Read More Add to Saved list

Academic Journal

The Synergistic Effect of Reduced Graphene Oxide and Proteasome Inhibitor in the Induction of Apoptosis through Oxidative Stress in Breast Cancer Cell Lines.

Authors : Krętowski, Rafał¹ (AUTHOR) ; Szynaka, Beata² (AUTHOR) ; Jabłońska-Trypuć, Agata³ (AUTHOR)

Source: International Journal of Molecular Sciences. May2024, Vol. 25 Issue 10, p5436. 23p.

Record details

Read Online Read More Add to Saved list

Academic Journal

The Proteasome Inhibitor CEP-18770 Induces Cell Death in Medulloblastoma.

Authors : Nath Varma, Swastina¹ (AUTHOR) ; Ye, Shany² (AUTHOR) ; Ferlin, Sara² (AUTHOR)

Source: Pharmaceutics. May2024, Vol. 16 Issue 5, p672. 15p.

Record details

Read Online Read More Add to Saved list

Academic Journal

MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.

Authors : Wang, Xiaobin^1,2 (AUTHOR); Shi, Yingqing³ (AUTHOR); Shi, Hua⁴ (AUTHOR)

Source: Journal of Experimental & Clinical Cancer Research (17569966). 3/5/2024, Vol. 43 Issue 1, p1-21. 21p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects.

Authors : AlZahrani, Abdullah¹ (AUTHOR) ; Alsuhebany, Nada^2,3,4 (AUTHOR); Tailor, Imran K.⁵ (AUTHOR)

Source: Hematology. Dec2024, Vol. 29 Issue 1, p1-7. 7p.

Record details

Read Online Read More Add to Saved list

Search Results

Your Filters

Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment.

First-Line Combination with Proteasome Inhibitor-Based Treatment and Zoledronic Acid Is Effective in Reducing Later Fractures in Multiple Myeloma Irrespective of Multiple Myeloma Bone Disease at Diagnosis.

The Proteasome Inhibitor Marizomib Evokes Endoplasmic Reticulum Stress and Promotes Apoptosis in Human Glioblastoma Cells.

The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer.

Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.

Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties.

The Synergistic Effect of Reduced Graphene Oxide and Proteasome Inhibitor in the Induction of Apoptosis through Oxidative Stress in Breast Cancer Cell Lines.

The Proteasome Inhibitor CEP-18770 Induces Cell Death in Medulloblastoma.

MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.

Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects.

Contact

Follow us